Perianal fistulizing Crohn's disease represents a specific and therapeutically demanding manifestation of Crohn's disease. Achieving fistula closure and stopping drainage requires a targeted, evidence-based approach.
This protocol addresses patients with Crohn's disease complicated by perianal fistulizing disease. Managing this phenotype requires dedicated treatment selection beyond standard luminal disease therapy.
Cessation of perianal fistula drainage and fistula closure.
Alternative advanced therapies are used for the induction of remission of perianal fistulizing Crohn's disease. The full structured protocol specifies which agents apply and under what clinical conditions — access it below.
DOI: 10.14309/ajg.0000000000003465;
We recommend infliximab use for induction of remission of perianal fistulizing CD (strong recommendation, moderate level of evidence).
We suggest vedolizumab use for induction of remission of perianal fistulizing CD (conditional recommendation, very low level of evidence).
We suggest ustekinumab for induction of remission of perianal fistulizing CD (conditional recommendation, very low level of evidence).
We suggest upadacitinib use for induction of remission of perianal fistulizing CD (conditional recommendation, very low level of evidence).
View source ↗